Researchers behind Replimune's melanoma study offer a rare protest of FDA's CRL

Typically, when the FDA sends out a CRL to a biotech for something other than, say, a routine manufacturing issue, the biotech puts out a vaguely-worded response about seeking clarity and then hunkers down to ...